<!DOCTYPE  html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8"/><title>4 Breast</title><link href="navigation.css" rel="stylesheet" type="text/css"/><link href="document.css" rel="stylesheet" type="text/css"/></head><body><p class="top_nav"><a href="part9.htm">&lt; Назад</a><span> | </span><a href="../index.html">Содержимое</a><span> | </span><a href="part11.htm">Далее &gt;</a></p><p style="padding-top: 4pt;padding-left: 55pt;text-indent: 0pt;text-align: left;"><a href="#bookmark9" class="s17" name="bookmark39">Chapter 4</a><a name="bookmark40">&zwnj;</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 55pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="374" height="1" alt="image" src="Image_033.png"/></span></p><p style="padding-top: 4pt;padding-left: 55pt;text-indent: 0pt;text-align: left;"><h2 href="#bookmark9">Breast</h2></p><p class="s18" style="padding-top: 10pt;padding-left: 53pt;text-indent: 0pt;text-align: left;">dinos Geropantas and Victoria ames</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s19" style="padding-top: 13pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">4.1 <span class="h4">Clinical background</span></p><p class="s28" style="padding-top: 6pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">4.1.1 <span class="s29">Incidence</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Breast cancer is the most common cancer in women in the UK, with an estimated life- time risk of 1 in 7 (15%) for all women born after 1960. There were nearly 55,000 new cancer diagnoses in 2015, accounting for 15% of all new cancer cases, though only 1% of these cancers were in men. Since the early 1990s, there has been a steady increase in breast cancer incidence rates, reflecting the changing risk factor profiles as well as the improving diagnostic techniques and the more accurate data recording.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Breast cancer incidence remains strongly associated with age, with over 25% of new cases in 2013–15 in people aged over 75. Hereditary factors only account for about 25% of breast cancer risk. Although the genetic mutations of BRCA1 and BRCA2 confer a high risk of developing breast cancer (45–65% by age 70), as they are uncommon (affecting approximately 1 in 450 women) they only account for about 2% of breast cancers overall. It is estimated that 23% of breast cancer cases are preventable, with risk factors such as obesity and alcohol each accounting for up to 8% of cases diagnosed.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Up to 87% of cancer cases in the UK are at an early stage (I or II) at the time of diagnosis, with only 7% of cases having evidence of metastatic disease at presentation. A late stage of disease at diagnosis is associated with older age (over 80) and social deprivation.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Breast cancer mortality rates in the UK have fallen dramatically since 1971, with a decrease of 38% in females and 45% in males. The reduction in breast cancer mor- tality rates is likely to have several different causes, including screening, increasing availability of standardized specialist care, and advances in diagnostic methods and therapies.</p><p class="s28" style="padding-top: 9pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">4.1.2 <span class="s29">Screening</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">In 2017–18, the UK NHS breast screening programme (NHSBSP) screened 2.1 mil- lion women aged over 45 years, seeing a 34% increase in the uptake of screening in the ten years preceding, with over 70% taking up their invitation to be screened. Of the</p><p style="padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">2.1 million women screened, 18,001 women were diagnosed with cancer, providing a cancer detection rate of 8.4 cases per 1000 women screened. There is a notable spike in overall breast cancer incidence at around 50 when routine breast screening starts.</p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Screening of those individuals with a documented increased risk of breast cancer, is well established and is predominantly performed with a combination of mammog- raphy and/or contrast-enhanced magnetic resonance imaging (MRI). The imaging modality and screening interval is dictated by the individual’s risk category (e.g. BRCA carrier status, TP53, supradiaphragmatic radiotherapy irradiated below 30), and age. Although standard practice in many parts of Europe and the USA, routine screening or surveillance with ultrasound (US) is not recommended in the UK.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Non-invasive and micro-invasive disease accounts for approximately 20% of screen- detected cancers. Ductal carcinoma <i>in situ </i>(DCIS) registrations have increased mark- edly since the introduction of breast screening, because it is a condition that is not usually palpable and therefore is mostly diagnosed by mammography. Critics of the breast screening programme have voiced concerns that identifying DCIS can lead to unnecessary diagnosis of breast tumours, as the low- to intermediate-grade histo- logical subtypes may never progress or threaten the woman’s life. Small studies have reported progression to invasive disease rates of 39–53%. These series included pa- tients diagnosed with invasive disease who had a history of an incorrectly labelled ‘benign’ excisional biopsy in the past which on review appeared positive for DCIS. Of interest, low-grade pathology did not predict a benign course. Autopsy studies suggest a median prevalence of DCIS of 8.9%. However, the majority of screen-detected DCIS is high grade and necrotic and given that this is the histological subtype that develops into high-grade invasive cancer, its early detection and treatment aims to improve the prognosis for these more aggressive tumours.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s19" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">4.2 <span class="h4">Diagnosis and staging</span></p><p class="s28" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">4.2.1 <span class="s29">Radiological diagnosis</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Despite advances in imaging techniques over the last two decades, in particular MRI, the main diagnostic tools used radiologically in the diagnosis of breast cancer remain mammography and US. In women younger than 40 years of age mammography is not routinely performed in the assessment of a breast lesion, as the breasts are radiograph- ically dense and therefore difficult to interpret mammographically. As a result, US remains the primary imaging modality for this group.</p><p class="s28" style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">4.2.1.1 <span class="s66">Mammography</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">In women of 40 years and over, a mammogram is the first-line investigation, often accompanied by a focused US of the area of clinical concern. The routine use of full field digital mammography has improved diagnostic accuracy when compared to film-screen mammography, with the additional benefits of image manipulation and electronic image transfer.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The most common mammographic feature of breast cancer is a dense mass with an ill-defined border; though a spiculate irregular mass has a pathognomonic appearance (Figure 4.1). Usually, a well-marginated mass on a mammogram represents a benign entity such as a simple cyst, a fibroadenoma, or an intramammary node. However, some invasive cancers can mimic these entities. Therefore, histological confirmation</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 111pt;text-indent: 0pt;text-align: left;"><span><img width="163" height="234" alt="image" src="Image_034.jpg"/></span></p><p class="s24" style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 117%;text-align: left;">Fig. 4.1 <span class="s25">left craniocaudal mammogram confirming a spiculate mass in the central breast with associated architectural distortion (arrow).</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">via US-guided biopsy is usual practice for a new solid lesion in women over 25 years, or of any age if atypical.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Another mammographic sign of cancer is an architectural distortion of the breast tissue. This may be seen on only one mammographic view and can be very subtle. Post- surgical scarring, fat necrosis, radial scar, and sclerosing adenosis are all benign entities that show distortion or sometimes even a spiculate mass and hence can be indistin- guishable mammographically from cancer and require US correlation. The emergence of techniques such as digital breast tomosynthesis has enabled improved accuracy in the assessment of these more diagnostically challenging lesions, as well as asymmet- rical densities—the latter is usually secondary to composite shadowing from normal breast parenchyma (Figure 4.2). Digital breast tomosynthesis is a mammographic technique in which an arc of images is taken in both planes of the breast. The im- ages obtained are then post-processed to provide a 3D-like reconstructed image of the breast parenchyma. This has the objective of overcoming the effects of summation artefact present in conventional 2D mammography, with the aim of improving diag- nostic sensitivity and specificity.</p><p style="padding-left: 19pt;text-indent: 0pt;line-height: 11pt;text-align: justify;">Another mammographic feature of cancer is calcification. This is a common</p><p style="padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">mammographic finding associated with both benign and malignant pathology. Unfortunately, due to the poor mammographic specificity and sonographic sensitivity, most presentations remain indeterminate on imaging. As such, when calcification is indeterminate or suspicious, a mammographically-guided stereotactic biopsy is usu- ally performed. Many units now use a vacuum-assisted biopsy technique with large 10 G needles to increase the volume of tissue retrieved. This optimizes the chance of providing a definitive diagnosis as compared to standard 14G biopsy devices. With improving imaging techniques, more subtle findings are being identified and tar- geted for sampling under imaging guidance. As a result, there has been an increased</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="328" height="222" alt="image" src="Image_035.jpg"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s24" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 117%;text-align: left;">Fig. 4.2 <span class="s25">Single mediolateral oblique view right breast digital tomosynthesis confirming the known spiculate mass within the central breast (arrow) but also identifying a second lesion within the upper half of the breast (arrowhead).</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">interest in homogenizing the management of these histologically indeterminate (B3) lesions, some of which confer a significant malignancy (B5) upgrade rate (Table 4.1). For this reason, the practice of vacuum-assisted excision of B3 lesions under either US or stereotactic guidance has become a well-established technique in the UK, with the publication of NHSBSP guidelines on the same.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Over the last five years, contrast-enhanced spectral mammography (CESM) has grown as a technique, becoming integrated into the standard imaging pathway for many units for those patients presenting with a clinically suspicious mass, replacing the use of conventional four-view mammography. The technique utilizes intravenous iodinated contrast medium to provide a more accurate assessment of disease extent. However, as with the use of iodinated contrast in general radiology, there are contra- indications that require recognition and which need to be carefully managed. The use</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s24" style="padding-top: 5pt;padding-left: 38pt;text-indent: 0pt;text-align: left;">Table 4.1 <span class="s25">Core biopsy reporting categories</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 38pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="345" height="1" alt="image" src="Image_036.png"/></span></p><p class="s41" style="padding-top: 2pt;padding-bottom: 2pt;padding-left: 38pt;text-indent: 0pt;text-align: left;">B1            normal tissue</p><p style="padding-left: 38pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="345" height="1" alt="image" src="Image_037.png"/></span></p><p class="s41" style="padding-top: 2pt;padding-bottom: 2pt;padding-left: 38pt;text-indent: 0pt;text-align: left;">B2            Benign lesion</p><p style="padding-left: 38pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="345" height="1" alt="image" src="Image_038.png"/></span></p><p class="s41" style="padding-top: 2pt;padding-bottom: 2pt;padding-left: 38pt;text-indent: 0pt;text-align: left;">B3            lesion of uncertain malignant potential</p><p style="padding-left: 38pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="345" height="1" alt="image" src="Image_039.png"/></span></p><p class="s41" style="padding-top: 2pt;padding-bottom: 2pt;padding-left: 38pt;text-indent: 0pt;text-align: left;">B4            Suspicious</p><p style="padding-left: 38pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="345" height="1" alt="image" src="Image_040.png"/></span></p><p class="s41" style="padding-top: 2pt;padding-bottom: 2pt;padding-left: 38pt;text-indent: 0pt;text-align: left;">B5            malignant</p><p style="padding-left: 38pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="345" height="1" alt="image" src="Image_041.png"/></span></p><p class="s41" style="padding-top: 2pt;padding-bottom: 2pt;padding-left: 38pt;text-indent: 0pt;text-align: left;">B5a            <i>In situ</i></p><p style="padding-left: 38pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="339" height="1" alt="image" src="Image_042.png"/></span></p><p class="s41" style="padding-top: 2pt;padding-bottom: 2pt;padding-left: 38pt;text-indent: 0pt;text-align: left;">B5b            Invasive</p><p style="padding-left: 38pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="345" height="1" alt="image" src="Image_043.png"/></span></p><p class="s41" style="padding-top: 2pt;padding-bottom: 2pt;padding-left: 38pt;text-indent: 0pt;text-align: left;">B5c            not clear if invasive or <i>in situ</i></p><p style="padding-left: 38pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="339" height="1" alt="image" src="Image_044.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="249" height="323" alt="image" src="Image_045.jpg"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p class="s24" style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 117%;text-align: left;">Fig. 4.3 <span class="s25">Contrast-enhanced spectral left breast mammography, low kV (a) and (c) and recombined view (b) and (d) demonstrating multicentric enhancing malignancy (arrowheads) within complex heterogeneous breast parenchymal background.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">of CESM aims to streamline the staging pathway for patients with breast cancer, par- ticularly those with poorly marginated or multifocal/multicentric disease (Figure 4.3), with the aim of negating the need for MRI staging studies, and the frequently encoun- tered sequelae examinations.</p><p class="s28" style="padding-top: 7pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">4.2.1.2 <span class="s66">Ultrasound</span></p><p style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">On US, cancers are typically solid, low-echogenicity masses with irregular margins. Other features such as acoustic shadowing are present to a varying extent dependent on the make-up of the tumour (Figure 4.4). It is this variability in the sonographic ap- pearance of breast cancers that strengthens the argument to maintain a low threshold for percutaneous sampling of new or atypical solid masses. The role of other US tech- niques such as colour doppler and elastography remain under debate and have not yet become generally established into routine practice.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">It is standard practice to assess the ipsilateral axillary nodes with US for size and morphology at the time of the initial breast assessment. However, US has significant limitations, with one third of morphologically normal lymph nodes being confirmed metastatic at histology. Despite this, given the absence of an alternative technique, it remains the gold standard for preoperative axillary assessment. If a node is indeter- minate or abnormal, then percutaneous sampling with US-guided fine needle aspir- ation (FNA) or biopsy is indicated.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 53pt;text-indent: 0pt;text-align: left;"><span><img width="302" height="241" alt="image" src="Image_046.jpg"/></span></p><p class="s24" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 117%;text-align: left;">Fig. 4.4 <span class="s25">Breast uS confirming an irregular hypoechoic mass with some posterior acoustic shadowing, typical of a breast carcinoma (arrows).</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The internal mammary nodal chain (IMC) is usually involved by spread from su- perior and medial tumours, although axillary disease is still more common in patients with tumours at those sites. Due to the parasternal location of the nodes, they are not usually suitable for assessment with US and are therefore not standardly assessed unless further imaging with MRI, CT, or PET-CT (positron emission tomography) is undertaken.</p><p class="s28" style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">4.2.1.3 <span class="s66">MRI</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Dynamic contrast-enhanced breast MRI (Figure 4.5) has been shown to have a high sensitivity for the detection of invasive breast cancer, but traditionally at the expense of a variable specificity. There is also increasing evidence that high-grade necrotic DCIS, which is often non-calcified and therefore mammographically invisible, can be de- tected with MRI but this is not always reliable. The high detection rate is underpinned by the tendency of breast cancer (like other malignant tumours) to develop malignant angiogenesis. When gadolinium-DTPA contrast is administered intravenously, on T1- weighted images, there is an intense peak with subsequent washout (reflecting leaking capillaries). Lesion morphology as well as its time intensity curve aims to help risk stratify enhancing lesions. However, this remains relatively non-specific, with a re- sulting reliance on second-look US, MRI guided biopsy, or MRI follow-up to provide guidance on clinical significance.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Breast MRI has a well-established role in screening for breast cancer in those pa- tients identified to be at high risk, following the publication of National Institute for Health and Clinical Excellence (NICE) guidance. This guidance was evidenced by trials such as the UK MARIBS and advised a screening protocol involving an- nual MRI +/- mammography at differing schedules dictated by the individual genetic risk.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 59pt;text-indent: 0pt;text-align: left;"><span><img width="297" height="240" alt="image" src="Image_047.jpg"/></span></p><p class="s24" style="padding-top: 6pt;padding-left: 11pt;text-indent: 0pt;line-height: 117%;text-align: left;">Fig. 4.5 <span class="s25">Contrast-enhanced dynamic breast mrI study confirming a centrally necrotic left breast carcinoma (arrow) with associated nipple retraction (arrowhead).</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s28" style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">4.2.1.4 <span class="s66">PET/CT</span></p><p class="s65" style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">18<span class="s44">F-fluorodeoxyglucose positron emission tomography (</span>18<span class="s44">F-FDG-PET) imaging util- izes functional data to detect malignancy and has been shown to be able to detect breast carcinoma. When fused with computed tomography (PET/CT), the functional- anatomical detail provides a sensitive map for malignancy. However, the poor spatial resolution limits its sensitivity for primary breast carcinoma when comparing it with conventional mammography and MRI. The introduction of positron emission mam- mography (PEM) overcomes this issue but has the disadvantages of cost, availability of the technique, and radiation dose.</span></p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">PET/CT has been found to be useful in the assessment of silicone-laden nodes in the context of breast cancer with ruptured breast implants. Silicone-laden nodes cannot be formally assessed with US due to the obscuration of the nodal anatomy by the echogenic silicone. <span class="s22">18</span>F-FDG PET/CT can demonstrate differential FDG-avidity between non- metastatic silicone nodes and those with co-existent metastatic disease (Figure 4.6).</p><p class="s28" style="padding-top: 7pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">4.2.1.5 <span class="s66">Other considerations</span></p><p style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">The breast radiologist routinely uses excision or mastectomy specimen radiography to assess for the presence of tumour within the specimen as well as the apparent extent of disease relative to the specimen margins. Specimen radiographs are used not only at the time of percutaneous biopsy but also in the peri-operative setting.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The use of hydrophilic localization clips is standard practice within all breast imaging units in the UK. They are implanted percutaneously and provide multiple functions, including cross-correlation of biopsy sites between different imaging techniques and marking tumour sites prior to neoadjuvant chemotherapy to aid pre-surgical localiza- tion in the presence of significant disease response.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 99pt;text-indent: 0pt;text-align: left;"><span><img width="182" height="279" alt="image" src="Image_048.gif"/></span></p><p class="s24" style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;line-height: 117%;text-align: left;">Fig. 4.6 <span class="s81">18</span><span class="s82">f-fdG Pet/Ct confirming differential avidity in enlarged silicone laden nodes in the right axilla and enlarged metastatic nodes in the left axilla.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Artificial intelligence (AI) and other deep learning technologies continue to gain traction in breast cancer diagnostics. Algorithms can be applied either to a digital mammography unit or an MRI workstation with the aim to flag abnormal areas on the mammogram (or MRI) by producing electronic markers on the image at the touch of a button. It aims to provide a system that has benchmark screen reading indicators at least as good as trained film readers so as to provide a solution to the current UK workforce shortages. Work continues to develop in this area with no systems currently in standard practice within the UK.</p><p class="s28" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">4.2.2 <span class="s29">Radiological staging</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">The eighth edition of the AJCC TNM (tumour, node, metastasis) system has been widely adopted, and is being increasingly influenced by imaging techniques. Primary disease radiological staging continues to be performed routinely by mammography and US, which although reasonable in accuracy when correlated to final pathology are not perfect. Conventional imaging techniques have significant limitations in as- sessing disease extent in the context of dense parenchyma, poorly marginated lesions, non-calcified <i>in situ </i>disease, and multifocal tumours. Some tumour subtypes are more difficult to locally stage: lobular carcinoma is classically very difficult to measure as it often grows by infiltrating along normal tissue planes without forming a mass.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Dynamic contrast-enhanced MRI has improved accuracy at assessing local sta- ging in these more challenging cases and identifies additional cancer in 16% of pa- tients. However, the relatively poor specificity (positive predictive value 66%) has been blamed for unnecessarily increasing the extent of breast surgery for some women.</p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">These factors, coupled with the cost, the need to assess any indeterminate additional findings with targeted US, and the limited availability of MR-guided biopsy services act to disadvantage this technique.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">CESM demonstrates a comparable sensitivity to MRI for staging of local disease, but with some published papers suggesting a slightly improved false positive rate. Given the easy access to mammography and contrast, the low relative costs and potential for time-saving in the patient pathway, CESM is an attractive imaging alternative for locoregional staging in some breast units.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">CT with or without isotope bone scan remains the standard imaging modality to assess for metastatic disease. However, the increasing experience with PET/CT in breast cancer patients has enabled formal guidance to be published. Although it has limitations in characterizing sub-centimetre lesions, development of the techniques including increased experience, fusion with other imaging modalities and novel tracers are improving this issue. In 2016, the Royal College of Radiologist (RCR)/Royal College of Physicians (RCP) provided a set of accepted indications for PET/CT in breast cancer:</p><p style="padding-top: 1pt;padding-left: 23pt;text-indent: -12pt;line-height: 94%;text-align: left;">1. Assessment of multi-focal disease or suspected recurrence in patients with dense breasts.</p><p style="padding-top: 2pt;padding-left: 23pt;text-indent: -12pt;line-height: 94%;text-align: left;">2. Differentiation of treatment-induced brachial plexopathy from tumour infiltration in symptomatic patients with an equivocal or normal MRI.</p><p style="padding-top: 2pt;padding-left: 23pt;text-indent: -12pt;line-height: 94%;text-align: left;">3. Assessment of extent of disease in selected patients with disseminated breast cancer before therapy.</p><p style="padding-top: 2pt;padding-left: 23pt;text-indent: -12pt;line-height: 94%;text-align: left;">4. Assessment of response to chemotherapy in patients whose disease is not well dem- onstrated using other techniques; for example bony metastases (Figure 4.7).</p><p style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">There is much interest in the use of other tracers such as <span class="s22">18</span>F-flouride for bony disease as they provide a fine-tuning role in the development of PET/CT. However, their place in breast cancer management in the NHS will require evidence to support their cost effectiveness.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Metastatic disease can present either <i>de novo </i>or usually within 2–5 years after diag- nosis (within 2–3 years in triple negative breast cancers—TNBC). Differences in pat- terns of spread among various histological types of breast cancer and among various biological profiles of the tumour need to be taken into account when imaging is con- sidered. ER-positive/Her2-negative tumours are more likely to metastasize to bones, but can also spread to lungs, liver, and brain. TNBC has a tendency to metastasize pri- marily to lung, liver, and brain. HER2-positive breast cancer can involve the CNS more frequently, particularly in patients treated with anti-HER2 targeted therapies. Invasive lobular tumours can exhibit a distinct pattern of metastatic spread and compared with ductal tumours they have a higher likelihood of gastrointestinal, ovarian, and omental involvement. Radiological investigations in patients with known metastatic disease should be guided by symptoms.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Bone metastases are classified as lytic, sclerotic, or mixed. Bone scan is a sensitive imaging modality routinely used in their diagnosis and it commonly demonstrates increased uptake in the affected areas (hotspots), while in cases of extensive skeletal involvement a ‘superscan’ can be observed. Large lytic lesions can sometimes appear as photopenic areas (cold spots) (Figure 4.8). CT can demonstrate pathological fractures</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="416" height="341" alt="image" src="Image_049.jpg"/></span></p><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s24" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 117%;text-align: left;">Fig. 4.7 <span class="s25">(a) Pet/Ct images demonstrating response to neo-adjuvant chemotherapy in a patient with subtle indeterminate distant findings in the lungs and bones. (b) Pet/Ct study performed to characterize an incidental sub-solid lung mass in the right lower lobe identified on Ct staging for breast cancer. Images confirmed that bilateral sub-centimetre nodules thought to be intrapulmonary nodes on conventional Ct were actually pulmonary metastases.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="416" height="231" alt="image" src="Image_050.jpg"/></span></p><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s24" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 117%;text-align: left;">Fig. 4.8 <span class="s25">Bone scan showing increased uptake at the sternum with central photopaenia in keeping with a metastasis (red arrow). Ct scan confirms a 45 mm x 26 mm destructive bone lesion in the upper sternum (yellow arrow).</span></p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">and provide detailed information on the structural integrity of the spine, but MRI is better at identifying epidural and bone marrow infiltration and describing the extent of extraosseous soft tissue component.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Chest radiography can help diagnose pleural effusions but a CT scan is required to identify lung and pleural metastases, and mediastinal nodes. Multidetector CT in- volves thin slice imaging, also providing an excellent opportunity for detecting other processes such as lymphangitis carcinomatosa.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Liver metastases can be seen as hypoechoic lesions on US and sometimes appear as ‘target’ lesions. They will usually present as low attenuation lesions on CT, with vari- able enhancement in the portal venous phase of scanning. Occasionally a more diffuse pattern of infiltrative disease is observed, which makes the liver appear cirrhotic-like or ‘pseudocirrhotic’. MRI can be used if there is equivocation.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">A CT scan of the head is usually employed first to investigate symptoms suggestive of brain metastases, but contrast-enhanced MRI can provide a more definitive diag- nosis and much improves sensitivity for leptomeningeal disease.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s19" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">4.3 <span class="h4">Radiotherapy planning</span></p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Most patients treated with breast conservation surgery (BCS) and a good proportion of those having a mastectomy (e.g. those with involved margins, T3–T4 tumours, node positive disease) will be considered for postoperative radiotherapy (RT). Usually the whole breast is treated, but in low-risk cases partial breast radiotherapy may be considered.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">In addition to breast and/or chest wall, the supraclavicular fossa (SCF) with or without the infraclavicular fossa (ICF) might need to be irradiated if there is in- creased risk of spread to this areas (e.g. always consider if ≥4 positive axillary nodes and sometimes if 1–3 positive nodes). Treatment to the axilla can be avoided in patients with a negative sentinel node. The same is true for patients with ITCs or micrometastasis in the sentinel node and for those with macrometastases in one or two nodes and otherwise T1, ER-positive, HER2-negative, grade 1–2 tumours, treated with BCS. Traditionally, patients requiring further axillary treatment would undergo a surgical clearance, but in recent years, axillary radiotherapy has been con- sidered a safe alternative in order to reduce the risk for lymphoedema (AMAROS study eligible patients—T1/T2). The IMC nodes should be targeted when involved; however, new evidence suggest that prophylactic IMC RT can be considered in those with T4 and/or N2–3 disease and perhaps even in those with N1 disease and central or medial tumours. A radiotherapy boost is considered in patients treated with BCS for invasive cancer and &lt;50 years of age or those ≥50 years with high-risk features (grade 3, etc.).</p><p style="padding-left: 19pt;text-indent: 0pt;line-height: 11pt;text-align: justify;">In the era of 2D conventional RT, a fluoroscopic simulator was used to plan the</p><p style="padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">treatment and bony landmarks were used to define the field borders. In the era of 3D- Conformal Radiotherapy (3DCRT) and more recently in that of Intensity Modulated Radiotherapy (IMRT) the target areas are carefully contoured on a RT planning CT scan. This is performed with the patient in supine position on a breast board either lying flat or slightly inclined with the arms abducted. A maximum slice thickness of</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="416" height="160" alt="image" src="Image_051.jpg"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s24" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 117%;text-align: left;">Fig. 4.9 <span class="s25">axial and coronal images of radiotherapy planning Ct scan. from medial to lateral CtVn_l4, CtVn_l3, CtVn_l2, CtVn_l1 can be seen in both images. CtVn_ interpectoralis can be seen anterior to CtVn_l2 on the axial image (between pectoralis major and pectoralis minor muscles).</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">2–3 mm should be aimed for, and IV contrast should be administered in order to better visualize the axillary, low neck, and internal mammary vessels.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The European Society for Radiotherapy and Oncology (ESTRO) has published a consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer, describing in detail the anatomical borders of breast/chest wall and nodal clinical target volumes (CTVs) (Figure 4.9) (Table 4.2).</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">ESTRO has also published a consensus guideline for target volume delineation in the setting of postmastectomy radiation therapy after implant-based immediate breast reconstruction (IBR) for early stage disease. It is suggested that after IBR with a pre- pectoral implant, the CTV includes the ventral part between skin and implant, which contains the subcutaneous lymphatic plexus and possible residual glandular tissue. The dorsal part between the implant and the pectoral muscle/chest wall, containing any residual glandular tissue can be either partially or completely incorporated in the CTV depending on the presence of adverse factors. These include large tumours (pT3), locally advanced breast cancer (LABC) in the absence of a pathological com- plete response to induction systemic anti-cancer therapy, and invasion of the major pectoral muscle and/or the chest wall. In cases of IBR with a retro-pectoral implant, if the dorsal fascia is not involved with tumour the CTV encompasses the subcutaneous lymphatic plexus but largely excludes the implant. In the presence of adverse factors as described above or in caudal breast tumours located adjacent to the dorsal fascia and not covered by the major pectoral muscle, clips can be used to demarcate the area and a separate dorsal CTV can be drawn.</p><p style="padding-left: 14pt;text-indent: 0pt;line-height: 11pt;text-align: justify;">A uniform margin is added to the CTV for the planning target volume (PTV) in</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">order to account for set-up errors. Two tangential fields are used to encompass the breast/chest wall PTV and a third vertical field is matched to the tangential fields su- periorly when the SCF (with or without the ICF) need to be irradiated. Wider tan- gential fields are required when the axilla and/or IMC is targeted. Inverse planning IMRT or arc RT (e.g. volumetric modulated arc therapy, rapid arc) can offer increased conformity and might be required for complex anatomy cases (e.g. when tangential</p><p class="s24" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Table 4.2 <span class="s25">eStro delineation guidelines for the CtV of lymph node regions, breast, and postmastectomy thoracic wall for elective irradiation in breast cancer</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:5.7756pt" cellspacing="0"><tr style="height:35pt"><td style="width:44pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;text-indent: 0pt;line-height: 112%;text-align: left;">Bordersper region</p></td><td style="width:82pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;padding-left: 4pt;padding-right: 31pt;text-indent: 0pt;line-height: 112%;text-align: left;">Axilla level 1 CTVn_L1</p></td><td style="width:68pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;padding-left: 3pt;padding-right: 19pt;text-indent: 0pt;line-height: 112%;text-align: left;">Axilla level 2 CTVn_L2</p></td><td style="width:64pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;padding-left: 3pt;padding-right: 13pt;text-indent: 0pt;line-height: 112%;text-align: left;">Axilla level 3 CTVn_L3</p></td><td style="width:76pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;padding-left: 2pt;text-indent: 0pt;line-height: 112%;text-align: left;">Lymph node level 4 CTVn_L4</p></td><td style="width:65pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;padding-left: 4pt;text-indent: 0pt;line-height: 112%;text-align: left;">Internal mammary chain CTVn_IMN</p></td><td style="width:60pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;padding-left: 3pt;text-indent: 0pt;line-height: 112%;text-align: left;">Interpectoral nodes CTVn_ interpectoralis</p></td><td style="width:65pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;padding-left: 3pt;text-indent: 0pt;line-height: 112%;text-align: left;">Residual breast CTVp_breast</p></td><td style="width:71pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;padding-left: 3pt;padding-right: 7pt;text-indent: 0pt;line-height: 112%;text-align: left;">Thoracic wall CTVp_thoracic wall</p></td></tr><tr style="height:12pt"><td style="width:44pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;line-height: 8pt;text-align: left;">Cranial</p></td><td style="width:82pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 4pt;text-indent: 0pt;line-height: 8pt;text-align: left;">medial: 5 mm cranial</p></td><td style="width:68pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 3pt;text-indent: 0pt;line-height: 8pt;text-align: left;">Includes the</p></td><td style="width:64pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 3pt;text-indent: 0pt;line-height: 8pt;text-align: left;">Includes the</p></td><td style="width:76pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;line-height: 8pt;text-align: left;">Includes the cranial</p></td><td style="width:65pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 4pt;text-indent: 0pt;line-height: 8pt;text-align: left;">Caudal limit of</p></td><td style="width:60pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 3pt;text-indent: 0pt;line-height: 8pt;text-align: left;">Includes the</p></td><td style="width:65pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 3pt;text-indent: 0pt;line-height: 8pt;text-align: left;">upper border of</p></td><td style="width:71pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 3pt;text-indent: 0pt;line-height: 8pt;text-align: left;">Guided by palpable/</p></td></tr><tr style="height:11pt"><td style="width:44pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:82pt"><p class="s27" style="padding-top: 1pt;padding-left: 9pt;text-indent: 0pt;line-height: 8pt;text-align: left;">to the axillary vein</p></td><td style="width:68pt"><p class="s27" style="padding-top: 1pt;padding-left: 3pt;text-indent: 0pt;line-height: 8pt;text-align: left;">cranial extent of</p></td><td style="width:64pt"><p class="s27" style="padding-top: 1pt;padding-left: 3pt;text-indent: 0pt;line-height: 8pt;text-align: left;">cranial extent of</p></td><td style="width:76pt"><p class="s27" style="padding-top: 1pt;padding-left: 2pt;text-indent: 0pt;line-height: 8pt;text-align: left;">extent of the</p></td><td style="width:65pt"><p class="s27" style="padding-top: 1pt;padding-left: 4pt;text-indent: 0pt;line-height: 8pt;text-align: left;">CtVn_l4</p></td><td style="width:60pt"><p class="s27" style="padding-top: 1pt;padding-left: 3pt;text-indent: 0pt;line-height: 8pt;text-align: left;">cranial extent</p></td><td style="width:65pt"><p class="s27" style="padding-top: 1pt;padding-left: 3pt;text-indent: 0pt;line-height: 8pt;text-align: left;">palpable/ visible</p></td><td style="width:71pt"><p class="s27" style="padding-top: 1pt;padding-left: 3pt;text-indent: 0pt;line-height: 8pt;text-align: left;">visible signs; if</p></td></tr><tr style="height:12pt"><td style="width:44pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:82pt"><p class="s27" style="padding-top: 1pt;padding-left: 4pt;text-indent: 0pt;line-height: 9pt;text-align: left;">lateral: maximally up</p></td><td style="width:68pt"><p class="s27" style="padding-top: 1pt;padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">the axillary artery</p></td><td style="width:64pt"><p class="s27" style="padding-top: 1pt;padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">the subclavian</p></td><td style="width:76pt"><p class="s27" style="padding-top: 1pt;padding-left: 2pt;text-indent: 0pt;line-height: 9pt;text-align: left;">subclavian artery</p></td><td style="width:65pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:60pt"><p class="s27" style="padding-top: 1pt;padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">of the axillary</p></td><td style="width:65pt"><p class="s27" style="padding-top: 1pt;padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">breast tissue;</p></td><td style="width:71pt"><p class="s27" style="padding-top: 1pt;padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">appropriate guided</p></td></tr><tr style="height:11pt"><td style="width:44pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:82pt"><p class="s27" style="padding-left: 9pt;text-indent: 0pt;line-height: 9pt;text-align: left;">to 1 cm below the</p></td><td style="width:68pt"><p class="s27" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">(i.e. 5 mm cranial</p></td><td style="width:64pt"><p class="s27" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">artery (i.e. 5 mm</p></td><td style="width:76pt"><p class="s27" style="padding-left: 2pt;text-indent: 0pt;line-height: 9pt;text-align: left;">(i.e. 5 mm cranial of</p></td><td style="width:65pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:60pt"><p class="s27" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">artery (i.e.</p></td><td style="width:65pt"><p class="s27" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">maximally up</p></td><td style="width:71pt"><p class="s27" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">by the contralateral</p></td></tr><tr style="height:11pt"><td style="width:44pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:82pt"><p class="s27" style="padding-left: 9pt;text-indent: 0pt;line-height: 9pt;text-align: left;">edge of the humeral</p></td><td style="width:68pt"><p class="s27" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">of axillary vein)</p></td><td style="width:64pt"><p class="s27" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">cranial of</p></td><td style="width:76pt"><p class="s27" style="padding-left: 2pt;text-indent: 0pt;line-height: 9pt;text-align: left;">subclavian vein)</p></td><td style="width:65pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:60pt"><p class="s27" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">5 mm cranial of</p></td><td style="width:65pt"><p class="s27" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">to the inferior</p></td><td style="width:71pt"><p class="s27" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">breast; maximally</p></td></tr><tr style="height:11pt"><td style="width:44pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:82pt"><p class="s27" style="padding-left: 9pt;text-indent: 0pt;line-height: 9pt;text-align: left;">head, 5 mm around</p></td><td style="width:68pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:64pt"><p class="s27" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">subclavian vein)</p></td><td style="width:76pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:65pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:60pt"><p class="s27" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">axillary vein)</p></td><td style="width:65pt"><p class="s27" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">edge of the</p></td><td style="width:71pt"><p class="s27" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">up to the inferior</p></td></tr><tr style="height:11pt"><td style="width:44pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:82pt"><p class="s27" style="padding-left: 9pt;text-indent: 0pt;line-height: 9pt;text-align: left;">the axillary vein</p></td><td style="width:68pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:64pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:76pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:65pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:60pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:65pt"><p class="s27" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">sternoclavicular</p></td><td style="width:71pt"><p class="s27" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">edge of the sterno-</p></td></tr><tr style="height:13pt"><td style="width:44pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:82pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:68pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:64pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:76pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:65pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:60pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:65pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">joint</p></td><td style="width:71pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">clavicular joint</p></td></tr><tr style="height:13pt"><td style="width:44pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;line-height: 9pt;text-align: left;">Caudal</p></td><td style="width:82pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 4pt;text-indent: 0pt;line-height: 9pt;text-align: left;">to the level of rib</p></td><td style="width:68pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">the caudalborder</p></td><td style="width:64pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">5 mm caudal to</p></td><td style="width:76pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;line-height: 9pt;text-align: left;">Includes the</p></td><td style="width:65pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 4pt;text-indent: 0pt;line-height: 9pt;text-align: left;">Cranial side of</p></td><td style="width:60pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">level 2’s caudal</p></td><td style="width:65pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">most caudal Ct</p></td><td style="width:71pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">Guided by palpable/</p></td></tr><tr style="height:11pt"><td style="width:44pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:82pt"><p class="s27" style="padding-left: 4pt;text-indent: 0pt;line-height: 9pt;text-align: left;">4–5, taking also into</p></td><td style="width:68pt"><p class="s27" style="padding-left: 8pt;text-indent: 0pt;line-height: 9pt;text-align: left;">of the pectoral</p></td><td style="width:64pt"><p class="s27" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">the subclavian</p></td><td style="width:76pt"><p class="s27" style="padding-left: 2pt;text-indent: 0pt;line-height: 9pt;text-align: left;">subclavian vein with</p></td><td style="width:65pt"><p class="s27" style="padding-left: 4pt;text-indent: 0pt;line-height: 9pt;text-align: left;">the 4th rib (in</p></td><td style="width:60pt"><p class="s27" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">limit</p></td><td style="width:65pt"><p class="s27" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">slice with visible</p></td><td style="width:71pt"><p class="s27" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">visible signs; if</p></td></tr><tr style="height:11pt"><td style="width:44pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:82pt"><p class="s27" style="padding-left: 4pt;text-indent: 0pt;line-height: 9pt;text-align: left;">account the visible</p></td><td style="width:68pt"><p class="s27" style="padding-left: 8pt;text-indent: 0pt;line-height: 9pt;text-align: left;">muscle</p></td><td style="width:64pt"><p class="s27" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">vein. If</p></td><td style="width:76pt"><p class="s27" style="padding-left: 2pt;text-indent: 0pt;line-height: 9pt;text-align: left;">5 mm margin, thus</p></td><td style="width:65pt"><p class="s27" style="padding-left: 4pt;text-indent: 0pt;line-height: 9pt;text-align: left;">selected cases</p></td><td style="width:60pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:65pt"><p class="s27" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">breast</p></td><td style="width:71pt"><p class="s27" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">appropriate guided</p></td></tr><tr style="height:11pt"><td style="width:44pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:82pt"><p class="s27" style="padding-left: 4pt;text-indent: 0pt;line-height: 9pt;text-align: left;">effects of the sentinel</p></td><td style="width:68pt"><p class="s27" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">If appropriate: top</p></td><td style="width:64pt"><p class="s27" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">appropriate:</p></td><td style="width:76pt"><p class="s27" style="padding-left: 2pt;text-indent: 0pt;line-height: 9pt;text-align: left;">connecting to the</p></td><td style="width:65pt"><p class="s27" style="padding-left: 4pt;text-indent: 0pt;line-height: 9pt;text-align: left;">5th rib)</p></td><td style="width:60pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:65pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:71pt"><p class="s27" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">by the contralateral</p></td></tr><tr style="height:11pt"><td style="width:44pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:82pt"><p class="s27" style="padding-left: 4pt;text-indent: 0pt;line-height: 9pt;text-align: left;">lymph node biopsy</p></td><td style="width:68pt"><p class="s27" style="padding-left: 8pt;text-indent: 0pt;line-height: 9pt;text-align: left;">of surgical alnd</p></td><td style="width:64pt"><p class="s27" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">top of surgical</p></td><td style="width:76pt"><p class="s27" style="padding-left: 2pt;text-indent: 0pt;line-height: 9pt;text-align: left;">cranial border of</p></td><td style="width:65pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:60pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:65pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:71pt"><p class="s27" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">breast</p></td></tr><tr style="height:13pt"><td style="width:44pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:82pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:68pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:64pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">alnd</p></td><td style="width:76pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">CtVn_Imn</p></td><td style="width:65pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:60pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:65pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:71pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:13pt"><td style="width:44pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;line-height: 9pt;text-align: left;">Ventral</p></td><td style="width:82pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 4pt;text-indent: 0pt;line-height: 9pt;text-align: left;">Pectoralis major and</p></td><td style="width:68pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">minor pectoral</p></td><td style="width:64pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">major pectoral</p></td><td style="width:76pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;line-height: 9pt;text-align: left;">Sternocleidomastoid</p></td><td style="width:65pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 4pt;text-indent: 0pt;line-height: 9pt;text-align: left;">Ventral limit of</p></td><td style="width:60pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">major pectoral</p></td><td style="width:65pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">5 mm under skin</p></td><td style="width:71pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">5 mm under skin</p></td></tr><tr style="height:11pt"><td style="width:44pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:82pt"><p class="s27" style="padding-left: 4pt;text-indent: 0pt;line-height: 9pt;text-align: left;">minor muscles</p></td><td style="width:68pt"><p class="s27" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">muscle</p></td><td style="width:64pt"><p class="s27" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">muscle</p></td><td style="width:76pt"><p class="s27" style="padding-left: 2pt;text-indent: 0pt;line-height: 9pt;text-align: left;">muscle, dorsal edge</p></td><td style="width:65pt"><p class="s27" style="padding-left: 4pt;text-indent: 0pt;line-height: 9pt;text-align: left;">the vascular area</p></td><td style="width:60pt"><p class="s27" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">muscle</p></td><td style="width:65pt"><p class="s27" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">surface</p></td><td style="width:71pt"><p class="s27" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">surface</p></td></tr><tr style="height:13pt"><td style="width:44pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:82pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:68pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:64pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:76pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">of the clavicle</p></td><td style="width:65pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:60pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:65pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:71pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:13pt"><td style="width:44pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;line-height: 9pt;text-align: left;">dorsal</p></td><td style="width:82pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 4pt;text-indent: 0pt;line-height: 9pt;text-align: left;">Cranially up to the</p></td><td style="width:68pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">up to 5 mm</p></td><td style="width:64pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">up to 5 mm</p></td><td style="width:76pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;line-height: 9pt;text-align: left;">Pleura</p></td><td style="width:65pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 4pt;text-indent: 0pt;line-height: 9pt;text-align: left;">Pleura</p></td><td style="width:60pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">minor pectoral</p></td><td style="width:65pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">major</p></td><td style="width:71pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">major pectoral</p></td></tr><tr style="height:11pt"><td style="width:44pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:82pt"><p class="s27" style="padding-left: 4pt;text-indent: 0pt;line-height: 9pt;text-align: left;">thoraco-dorsal vessels,</p></td><td style="width:68pt"><p class="s27" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">dorsal of axillary</p></td><td style="width:64pt"><p class="s27" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">dorsal of</p></td><td style="width:76pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:65pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:60pt"><p class="s27" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">muscle</p></td><td style="width:65pt"><p class="s27" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">pectoralmuscle</p></td><td style="width:71pt"><p class="s27" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">muscle or costae</p></td></tr><tr style="height:11pt"><td style="width:44pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:82pt"><p class="s27" style="padding-left: 4pt;text-indent: 0pt;line-height: 9pt;text-align: left;">and more caudally up</p></td><td style="width:68pt"><p class="s27" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">vein or to costae</p></td><td style="width:64pt"><p class="s27" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">subclavian vein</p></td><td style="width:76pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:65pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:60pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:65pt"><p class="s27" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">or costae and</p></td><td style="width:71pt"><p class="s27" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">and intercostal</p></td></tr><tr style="height:11pt"><td style="width:44pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:82pt"><p class="s27" style="padding-left: 4pt;text-indent: 0pt;line-height: 9pt;text-align: left;">to an imaginary line</p></td><td style="width:68pt"><p class="s27" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">and intercostal</p></td><td style="width:64pt"><p class="s27" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">or to costae</p></td><td style="width:76pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:65pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:60pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:65pt"><p class="s27" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">intercostal</p></td><td style="width:71pt"><p class="s27" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">muscles where no</p></td></tr><tr style="height:11pt"><td style="width:44pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:82pt"><p class="s27" style="padding-left: 4pt;text-indent: 0pt;line-height: 9pt;text-align: left;">between the anterior</p></td><td style="width:68pt"><p class="s27" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">muscles</p></td><td style="width:64pt"><p class="s27" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">and intercostal</p></td><td style="width:76pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:65pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:60pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:65pt"><p class="s27" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">muscles where</p></td><td style="width:71pt"><p class="s27" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">muscle</p></td></tr><tr style="height:11pt"><td style="width:44pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:82pt"><p class="s27" style="padding-left: 4pt;text-indent: 0pt;line-height: 9pt;text-align: left;">edge of the latissimus</p></td><td style="width:68pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:64pt"><p class="s27" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">muscles</p></td><td style="width:76pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:65pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:60pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:65pt"><p class="s27" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">no muscle</p></td><td style="width:71pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:11pt"><td style="width:44pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:82pt"><p class="s27" style="padding-left: 4pt;text-indent: 0pt;line-height: 9pt;text-align: left;">dorsi muscle and the</p></td><td style="width:68pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:64pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:76pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:65pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:60pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:65pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:71pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:10pt"><td style="width:44pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:82pt"><p class="s27" style="padding-left: 4pt;text-indent: 0pt;line-height: 8pt;text-align: left;">intercostal muscles</p></td><td style="width:68pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:64pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:76pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:65pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:60pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:65pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:71pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="785" height="1" alt="image" src="Image_052.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:5.7756pt" cellspacing="0"><tr style="height:13pt"><td style="width:35pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;line-height: 9pt;text-align: left;">medial</p></td><td style="width:89pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 12pt;text-indent: 0pt;line-height: 9pt;text-align: left;">level 2, the</p></td><td style="width:65pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 4pt;text-indent: 0pt;line-height: 9pt;text-align: left;">medial edge of</p></td><td style="width:67pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;line-height: 9pt;text-align: left;">Junction of</p></td><td style="width:79pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 4pt;text-indent: 0pt;line-height: 9pt;text-align: left;">Includes the jugular</p></td><td style="width:63pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">5 mm from</p></td><td style="width:60pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 4pt;text-indent: 0pt;line-height: 9pt;text-align: left;">medial edge of</p></td><td style="width:63pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 4pt;text-indent: 0pt;line-height: 9pt;text-align: left;">lateral to the</p></td><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 6pt;text-indent: 0pt;line-height: 9pt;text-align: left;">Guided by palpable/</p></td></tr><tr style="height:11pt"><td style="width:35pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:89pt"><p class="s27" style="padding-left: 12pt;text-indent: 0pt;line-height: 9pt;text-align: left;">interpectoral level</p></td><td style="width:65pt"><p class="s27" style="padding-left: 4pt;text-indent: 0pt;line-height: 9pt;text-align: left;">minor pectoral</p></td><td style="width:67pt"><p class="s27" style="padding-left: 9pt;text-indent: 0pt;line-height: 9pt;text-align: left;">subclavian and</p></td><td style="width:79pt"><p class="s27" style="padding-left: 4pt;text-indent: 0pt;line-height: 9pt;text-align: left;">vein without margin;</p></td><td style="width:63pt"><p class="s27" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">the internal</p></td><td style="width:60pt"><p class="s27" style="padding-left: 4pt;text-indent: 0pt;line-height: 9pt;text-align: left;">minor pectoral</p></td><td style="width:63pt"><p class="s27" style="padding-left: 4pt;text-indent: 0pt;line-height: 9pt;text-align: left;">medial</p></td><td style="width:74pt"><p class="s27" style="padding-left: 6pt;text-indent: 0pt;line-height: 9pt;text-align: left;">visible signs; if</p></td></tr><tr style="height:66pt"><td style="width:35pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:89pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-left: 12pt;text-indent: 0pt;text-align: left;">and the thoracic wall</p></td><td style="width:65pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">muscle</p></td><td style="width:67pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-left: 9pt;text-indent: 0pt;line-height: 112%;text-align: left;">internal jugular veins &gt;level 4</p></td><td style="width:79pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-left: 4pt;padding-right: 4pt;text-indent: 0pt;line-height: 112%;text-align: left;">excluding the thyroid gland and the common carotid artery</p></td><td style="width:63pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-left: 3pt;padding-right: 4pt;text-indent: 0pt;line-height: 112%;text-align: left;">mammary vein (artery in cranial part up to and including first intercostal space)</p></td><td style="width:60pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">muscle</p></td><td style="width:63pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-left: 4pt;padding-right: 5pt;text-indent: 0pt;line-height: 112%;text-align: left;">perforating mammary vessels; maximally to the edge of the sternal bone</p></td><td style="width:74pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-left: 6pt;padding-right: 1pt;text-indent: 0pt;line-height: 112%;text-align: justify;">appropriate guided by the contralateral breast</p></td></tr><tr style="height:13pt"><td style="width:35pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;line-height: 9pt;text-align: left;">lateral</p></td><td style="width:89pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 12pt;text-indent: 0pt;line-height: 9pt;text-align: left;">Cranially up to</p></td><td style="width:65pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 4pt;text-indent: 0pt;line-height: 9pt;text-align: left;">lateral edge of</p></td><td style="width:67pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;line-height: 9pt;text-align: left;">medial side</p></td><td style="width:79pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 4pt;text-indent: 0pt;line-height: 9pt;text-align: left;">Includes the anterior</p></td><td style="width:63pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">5 mm from</p></td><td style="width:60pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 4pt;text-indent: 0pt;line-height: 9pt;text-align: left;">lateral edge of</p></td><td style="width:63pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 4pt;text-indent: 0pt;line-height: 9pt;text-align: left;">lateral breast</p></td><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 6pt;text-indent: 0pt;line-height: 9pt;text-align: left;">Guided by palpable/</p></td></tr><tr style="height:11pt"><td style="width:35pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:89pt"><p class="s27" style="padding-left: 12pt;text-indent: 0pt;line-height: 9pt;text-align: left;">an imaginary line</p></td><td style="width:65pt"><p class="s27" style="padding-left: 4pt;text-indent: 0pt;line-height: 9pt;text-align: left;">minor pectoral</p></td><td style="width:67pt"><p class="s27" style="padding-left: 9pt;text-indent: 0pt;line-height: 9pt;text-align: left;">of the minor</p></td><td style="width:79pt"><p class="s27" style="padding-left: 4pt;text-indent: 0pt;line-height: 9pt;text-align: left;">scalene muscles</p></td><td style="width:63pt"><p class="s27" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">the internal</p></td><td style="width:60pt"><p class="s27" style="padding-left: 4pt;text-indent: 0pt;line-height: 9pt;text-align: left;">minor pectoral</p></td><td style="width:63pt"><p class="s27" style="padding-left: 4pt;text-indent: 0pt;line-height: 9pt;text-align: left;">fold; anterior</p></td><td style="width:74pt"><p class="s27" style="padding-left: 6pt;text-indent: 0pt;line-height: 9pt;text-align: left;">visible signs; if</p></td></tr><tr style="height:87pt"><td style="width:35pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:89pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-left: 12pt;padding-right: 7pt;text-indent: 0pt;line-height: 112%;text-align: left;">between the major pectoral and deltoid muscles, and further caudal up</p><p class="s27" style="padding-left: 12pt;padding-right: 6pt;text-indent: 0pt;line-height: 112%;text-align: left;">to a line between the major pectoral and latissimus dorsi muscles</p></td><td style="width:65pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">muscle</p></td><td style="width:67pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-left: 9pt;text-indent: 0pt;text-align: left;">pectoral muscle</p></td><td style="width:79pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-left: 4pt;text-indent: 0pt;line-height: 112%;text-align: left;">and connects to the medial border of CtVn_l3</p></td><td style="width:63pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-left: 3pt;padding-right: 4pt;text-indent: 0pt;line-height: 112%;text-align: left;">mammary vein (artery in cranial part up to and including first intercostal space)</p></td><td style="width:60pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">muscle</p></td><td style="width:63pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-left: 4pt;text-indent: 0pt;line-height: 112%;text-align: left;">to the lateral thoracic artery</p></td><td style="width:74pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-left: 6pt;text-indent: 0pt;line-height: 112%;text-align: left;">appropriate guided by the contralateral breast usually anterior to the mid- axillary line</p></td></tr></table><p class="s41" style="padding-top: 2pt;padding-bottom: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">alnd = axillary lymph node dissection.</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="798" height="1" alt="image" src="Image_053.png"/></span></p><p class="s21" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">reproduced with permission from offerson, B.V. et al. ‘eStro consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer’. <i>Radiotherapy and Oncology.</i></p><p class="s21" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Volume 114, Issue 1, pp. 3–10. Copyright © 2015 elsevier.</p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">fields cannot cover the IMC and spare the heart at the same time or in patients with corpus excavatum). A potential downside with these techniques is the irradiation of a larger area of lung, heart, and contralateral breast. In mastectomy patients, chest wall targeting can be aided by placing radio-opaque wires where it is clinically felt that the borders of the breast were located prior to surgery. A separate radio-opaque wire should be placed on the mastectomy scar to ensure it is fully encompassed in the chest wall CTV when possible.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Surgical clips should be placed in the tumour bed during the operation to facilitate targeting of the area for the breast boost. The boost CTV encompasses the tumour bed and all visible clips on planning CT and then a margin (usually 1 cm) is added to this for the boost PTV. The boost PTV should be treated with photons using a conformal technique (3DCRT or IMRT) unless electrons are felt more appropriate (e.g. in the case of a very superficial tumour bed). Defining the tumour bed on CT can prove dif- ficult in mammoplasty cases as often the clips have been pulled in different directions during this surgical procedure.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Image-guided radiotherapy (IGRT) is employed for treatment verification and pos- itional correction. IGRT techniques include the 2D megavoltage (2D-MV) portal imaging, the 2D kilovoltage planar imaging (2D-kVPI), the megavoltage CT (MV-CT) and the kV cone beam CT (CBCT). The bony anatomy and titanium surgical clips are used for the verification.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Radiation dose to the heart has been associated with increased risk of cardiac damage. For this reason, cardiac sparing techniques such as deep inspiration breath holding (DIBH), or active-breathing control (ABC) should be used in left breast/chest wall RT to minimize the dose to the heart.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s19" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">4.4 <span class="h4">Therapeutic assessment and follow-up</span></p><p class="s28" style="padding-top: 6pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">4.4.1 <span class="s29">Local control</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">For primary breast cancer that has been treated curatively, standard radiological follow- up is annual mammography for five years followed by discharge to the NHSBSP. For those patients who are less than 45 years at diagnosis, they are advised to have annual mammography until breast screening age. For patients who have had mastectomy, mammographic surveillance is for the contralateral side only, with clinical assessment providing the mainstay for screening the affected side.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Scar tissue can be difficult to assess mammographically. As it is heterogeneous, it can take a varying time to involute and may appear quite different between mammo- grams due to subtle differences in the way the breast is compressed. If there is clin- ical or mammographic suspicion of local scar recurrence at any time, then a focused US is appropriate. With the advent of MRI breast screening, those high-risk patients that develop a cancer should, post-treatment, continue with their annual MRI as well as annual mammography as per the NICE guidelines. The exception is the patient who has undergone bilateral mastectomy where no imaging surveillance is necessary. Contrast-enhanced MRI has the advantage of being highly sensitive in detecting re- current disease, though the previously discussed limitations of this technique remain.</p><p class="s28" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">4.4.2 <span class="s29">Toxicity and complications</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">A common early side-effect of radiotherapy is breast lymphoedema. On mammo- gram this appears as diffuse skin and trabecular thickening with interstitial oedema (Figure 4.10). Breast fat necrosis after surgery and radiotherapy needs to be differen- tiated from local tumour recurrence. Mammographically, it can present as a round oil cyst or as a subcutaneous asymmetric opacity with or without microcalcifications, while on US, subcutaneous tissue hyperechogenicity and/or a cyst can be demon- strated. Nonetheless, imaging cannot always provide a definite diagnosis and a biopsy might be required to exclude recurrent breast cancer. An uncommon effect of the combination of surgery and radiotherapy is benign dystrophic calcifications seen on a mammograph, but this rarely translates into actual clinical symptoms. Significant late breast fibrosis is not common, but when present the breast gland appears smaller, dense, and fibrotic on mammography as a result of the atrophy.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">A small strip of lung (usually &lt;2 cm) underlying the treated breast or thoracic wall is commonly included in the tangential fields and receives substantive doses of radiation. Similarly, the lung apex receives the exit dose from the vertical field used to treat the SCF/ICF. However, only a small percentage of patients will develop radiation pneu- monitis within six months of breast radiotherapy or radiation-induced lung fibrosis after six months. The lung changes on imaging will commonly follow the radiation beam path. A chest X-ray can show dense opacification but high-resolution computed tomography (HRCT) has better sensitivity and its findings can include ground glass attenuation, linear opacities, thickened septum, areas of atelectasis, and in more severe cases ‘honeycomb’ changes.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Ribs included in radiotherapy fields can appear slightly sclerotic on CT and a post- radiotherapy rib fracture can be identified on CT, bone scan, or even X-ray.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 53pt;text-indent: 0pt;text-align: left;"><span><img width="302" height="236" alt="image" src="Image_054.gif"/></span></p><p class="s24" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 117%;text-align: left;">Fig. 4.10 <span class="s25">axial turbo inversion recovery mrI sequence showing skin thickening and parenchymal oedema in the treated right breast.</span></p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Brachial plexopathy is a rare late complication of SCF irradiation and has a peak onset at 1–2 years from treatment. An MRI (or PET/CT) can sometimes help exclude obvious recurrent tumour that might be pressing on the brachial plexus. Radiation- induced plexopathy can present in the acute phase as symmetric nerve thickening with occasional T1 enhancement and increased nerve, muscle, and fat intensity on T2. In the late phase, contrast enhancement is absent but there is more thickening of nerves and reduced intensity on T2-weighted images.</p><p class="s28" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">4.4.3 <span class="s29">Metastases</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Metastatic patients staged with CT and started on systemic treatment can have a follow-up CT at three months to assess response to treatment. Bone scans are not as reliable in assessing treatment response in patients with bone metastases. Follow- up PET/CT scan can be used in those initially staged with PET/CT. The Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 is often used in clinical trials to assess response to systemic anti-cancer treatment on CT scans. Similar criteria have been developed for PET/CT (PET Response Criteria in Solid Tumours—PERCIST v.1.0).</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s19" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">4.5 <span class="h4">Summary</span></p><p class="s23" style="padding-top: 6pt;padding-left: 23pt;text-indent: -11pt;line-height: 94%;text-align: left;">◆ <span class="p">Mammography and US remain the primary diagnostic tools for breast cancer, though CESM and digital breast tomosynthesis are being utilized increasingly.</span></p><p class="s23" style="padding-top: 2pt;padding-left: 23pt;text-indent: -11pt;line-height: 94%;text-align: left;">◆ <span class="p">Secondary disease staging is performed typically with contrast enhanced CT and isotope bone scan, though PET/CT may have a role in advanced or complex disease.</span></p><p class="s23" style="padding-top: 2pt;padding-left: 23pt;text-indent: -11pt;line-height: 94%;text-align: left;">◆ <span class="p">Mammography and US are still performed for assessment of local recurrence, though MRI and PET/CT may have a role.</span></p><p class="s23" style="padding-top: 2pt;padding-left: 23pt;text-indent: -11pt;line-height: 94%;text-align: left;">◆ <span class="p">Modern conformal radiotherapy (3DCRT, IMRT) requires careful contouring of clinical target volumes with a contrast-enhanced CT scan.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s73" style="padding-left: 11pt;text-indent: 0pt;text-align: justify;">Further reading</p><p class="s74" style="padding-top: 5pt;padding-left: 24pt;text-indent: -12pt;text-align: left;">Brierley JD, Gospodarowicz MK, Wittekind C (eds) (2017). Breast in: <i>TNM Classification of Malignant Tumours </i>(eighth edition). Oxford: Wiley-Blackwell.</p><p class="s75" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">Cancer Research UK<span class="s74">. Available at: cancerresearchuk.org.</span></p><p class="s75" style="padding-top: 1pt;padding-left: 24pt;text-indent: -12pt;text-align: left;">Department of Health <span class="s74">(2016). Clinical guidelines for breast cancer screening assessment: fourth edition. NHSBSP Publication No 49; PHE publications gateway</span></p><p class="s74" style="padding-left: 24pt;text-indent: 0pt;text-align: left;"><a href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/567600/Clinical_guidance_for_breast__cancer_screening__assessment_Nov_2016.pdf" class="a" target="_blank">number: 2016426. Retrieved from: https://assets.publishing.service.gov.uk/government/ uploads/system/uploads/attachment_data/file/567600/Clinical_guidance_for_breast</a><span style=" color: #231F20; font-family:&quot;Palatino Linotype&quot;, serif; font-style: normal; font-weight: normal; text-decoration: underline; font-size: 8.5pt;"> </span><a href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/567600/Clinical_guidance_for_breast__cancer_screening__assessment_Nov_2016.pdf" class="a" target="_blank"> cancer_screening</a><a href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/567600/Clinical_guidance_for_breast__cancer_screening__assessment_Nov_2016.pdf" class="s84" target="_blank"> </a>assessment_Nov_2016.pdf.</p><p class="s74" style="padding-top: 1pt;padding-left: 24pt;text-indent: -12pt;text-align: left;"><b>Donker M</b>, <b>van Tienhoven G</b>, <b>Straver ME, et al. </b>(2014). Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. <i>Lancet Oncology</i>, <b>15</b>(12): 1303–1310.</p><p class="s74" style="padding-top: 4pt;padding-left: 18pt;text-indent: -12pt;text-align: left;"><b>Fallenberg EM</b>, <b>Schmitzberger FF</b>, <b>Amer H, et al. </b>(2017). Contrast-enhanced spectral mammography vs. mammography and MRI—clinical performance in a multi-reader evaluation. <i>European Radiology</i>, <b>27</b>(7): 2752–2764.</p><p class="s74" style="padding-top: 1pt;padding-left: 18pt;text-indent: -12pt;text-align: left;"><b>Kaidar-Person O</b>, <b>Vrou Offersen B</b>, <b>Hol S, et al. </b>(2019). ESTRO ACROP consensus guideline for target volume delineation in the setting of postmastectomy radiation therapy after implant-based immediate reconstruction for early stage breast cancer. <i>Radiotherapy &amp; Oncology</i>, <b>137</b>: 159–166.</p><p class="s74" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;"><b>Kuhl CK </b>(2007). Current status of breast MR imaging. Part 2. Clinical applications. <i>Radiology</i>,</p><p class="s75" style="padding-left: 18pt;text-indent: 0pt;line-height: 11pt;text-align: left;">244<span class="s74">(3): 672–691.</span></p><p class="s74" style="padding-top: 1pt;padding-left: 18pt;text-indent: -12pt;text-align: left;"><b>Leach MO</b>, <b>Boggis CR</b>, <b>Dixon AK, et al. </b>(2005). Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). <i>Lancet</i>, <b>365</b>(9473): 1769–1778.</p><p class="s75" style="padding-top: 1pt;padding-left: 18pt;text-indent: -12pt;text-align: left;">National Institute for Health and Care Excellence <span class="s74">(2013). Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer. Clinical guideline [CG164]. Published: June 2013 Last updated: March 2017.</span></p><p class="s74" style="padding-left: 18pt;text-indent: 0pt;text-align: left;"><a href="https://www.nice.org.uk/guidance/cg164/resources/familial-breast-cancer-classification-care-and-managing-breast-cancer-and-related-risks-in-people-with-a-family-history-of-breast-cancer-pdf-35109691767493" class="a" target="_blank">Available at: https://www.nice.org.uk/guidance/cg164/resources/familial-breast-cancer- classification-care-and-managing-breast-cancer-and-related-risks-in-people-with-a-family- </a>history-of-breast-cancer-pdf-35109691767493.</p><p class="s74" style="padding-top: 1pt;padding-left: 18pt;text-indent: -12pt;text-align: left;"><b>Offersen BV</b>, <b>Boersma LJ</b>, <b>Kirkove C, et al. </b>(2015). ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer. <i>Radiotherapy &amp; Oncology</i>, <b>114</b>(1): 3–10.</p><p class="s74" style="padding-top: 1pt;padding-left: 18pt;text-indent: -12pt;text-align: left;">The Royal College of Radiologists; Royal College of Physicians of London; Royal College of Physicians and Surgeons of Glasgow; Royal College of Physicians of Edinburgh; British Nuclear Medicine Society; Administration of Radioactive Substances Advisory Committee (2016). Evidence-based indications for the use of PET-CT in the United Kingdom 2016. <i>Clinical Radiology</i>, <b>71</b>(7): e171–188.</p><p class="s75" style="padding-top: 1pt;padding-left: 18pt;text-indent: -12pt;text-align: left;">The Royal College of Radiologists<a href="https://www.rcr.ac.uk/system/files/publication/field_publication_files/bfco2016_breast-consensus-guidelines.pdf" class="a" target="_blank">. Postoperative radiotherapy for breast cancer: UK consensus statements. London: The Royal College of Radiologists. Available at: https://www.rcr.ac.uk/ </a><span class="s74">system/files/publication/field_publication_files/bfco2016_breast-consensus-guidelines.pdf.</span></p><p class="nav">&nbsp;&nbsp;</p><p class="nav">&nbsp;</p><p class="nav"><a href="part9.htm">&lt; Назад</a><span> | </span><a href="../index.html">Содержимое</a><span> | </span><a href="part11.htm">Далее &gt;</a></p><p class="nav">&nbsp;&nbsp;</p></body></html>
